Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 10.95% and Operating profit at 12.21% over the last 5 years

Flat results in Jun 25

With ROE of 15.83%, it has a fair valuation with a 3.13 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 24,042 Million (Large Cap)

P/E

20.00

Industry P/E

Dividend Yield

1.32%

Debt Equity

-0.43

Return on Equity

15.83%

Price to Book

3.13

Revenue and Profits:

Net Sales:

1,479 Million

(Quarterly Results - Jun 2025)

Net Profit:

399 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.78%

6 Months

3.65%

1 Year

-7.25%

2 Years

-3.97%

3 Years

25.9%

4 Years

63.0%

5 Years

28.21%

Jiangsu Nhwa Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 25.35

Jiangsu Nhwa Pharmaceutical Co., Ltd. faced a notable stock price decline on October 14, 2025, reaching an intraday low. The company's recent performance has lagged behind the broader market, with declines over the past week and month, though it remains positive year-to-date. Financial metrics indicate solid returns and a dividend yield.

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 26.05

Jiangsu Nhwa Pharmaceutical Co., Ltd. faced a significant decline in stock value on October 13, 2025, reaching an intraday low. Despite this, the company has shown resilience with substantial long-term performance increases over three and five years, alongside a solid return on equity and favorable valuation metrics.

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 27.20

Jiangsu Nhwa Pharmaceutical Co., Ltd. faced a significant stock decline on September 30, 2025, reaching an intraday low. Despite a positive monthly performance and increased profits over the past year, the stock has struggled, reflecting challenges in the current trading environment. The company maintains solid financial metrics.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.95%

EBIT Growth (5y)

12.21%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.75

Tax Ratio

11.90%

Dividend Payout Ratio

31.72%

Pledged Shares

Institutional Holding

ROCE (avg)

36.36%

ROE (avg)

16.17%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.13

EV to EBIT

16.55

EV to EBITDA

13.73

EV to Capital Employed

4.74

EV to Sales

3.54

PEG Ratio

2.26

Dividend Yield

1.32%

ROCE (Latest)

28.60%

ROE (Latest)

15.83%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.59% vs 15.13% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.36% vs 13.38% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,479.20",
          "val2": "1,387.70",
          "chgp": "6.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "503.20",
          "val2": "467.90",
          "chgp": "7.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "1.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "399.40",
          "val2": "361.90",
          "chgp": "10.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "295.10%",
          "val2": "297.60%",
          "chgp": "-0.25%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.05% vs 17.27% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.31% vs 17.51% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,622.30",
          "val2": "4,973.50",
          "chgp": "13.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,446.70",
          "val2": "1,244.70",
          "chgp": "16.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.30",
          "val2": "5.00",
          "chgp": "6.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,140.80",
          "val2": "1,034.20",
          "chgp": "10.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "215.70%",
          "val2": "215.10%",
          "chgp": "0.06%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

1,479.20

1,387.70

6.59%

Operating Profit (PBDIT) excl Other Income

503.20

467.90

7.54%

Interest

0.60

1.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

399.40

361.90

10.36%

Operating Profit Margin (Excl OI)

295.10%

297.60%

-0.25%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 6.59% vs 15.13% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 10.36% vs 13.38% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5,622.30

4,973.50

13.05%

Operating Profit (PBDIT) excl Other Income

1,446.70

1,244.70

16.23%

Interest

5.30

5.00

6.00%

Exceptional Items

0.00

Consolidate Net Profit

1,140.80

1,034.20

10.31%

Operating Profit Margin (Excl OI)

215.70%

215.10%

0.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 13.05% vs 17.27% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 10.31% vs 17.51% in Dec 2023

All Annual Results

Company CV

About Jiangsu Nhwa Pharmaceutical Co., Ltd.

Jiangsu Nhwa Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Jiangsu Nhwa Pharmaceutical Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 10.95% and Operating profit at 12.21% over the last 5 years

Flat results in Jun 25

With ROE of 15.83%, it has a fair valuation with a 3.13 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 25.35

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 26.05

Jiangsu Nhwa Pharmaceutical Hits Day Low Amid Price Pressure at CNY 27.20

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Jiangsu Nhwa Pharmaceutical Co., Ltd.

Company Coordinates